FDA Endorses JN.1 Variant for Fall COVID Vaccines
TL;DR Summary
An FDA advisory panel has unanimously recommended updating the Covid-19 vaccine formula to target the JN.1 variant for the upcoming fall immunization campaign, despite newer variants like KP.2 and KP.3 emerging. The FDA is expected to finalize the variant target for vaccine manufacturers soon, aiming to improve protection against dominant strains.
- New Covid Vaccine Endorsed for Fall The New York Times
- FDA vaccine advisers vote unanimously in favor of updated Covid-19 shot for fall CNN
- FDA panel supports switch to JN.1 for fall COVID vaccines University of Minnesota Twin Cities
- COVID shots should target variants with JN.1 lineage in 2024-25 campaign, US FDA advisers say Reuters
- FDA panel picks JN.1 subvariant for fall COVID vaccines The Hill
Reading Insights
Total Reads
0
Unique Readers
21
Time Saved
2 min
vs 2 min read
Condensed
87%
385 → 51 words
Want the full story? Read the original article
Read on The New York Times